Skip to content

Earnings call

Sun Pharmaceutical Industries Q2 FY25 earnings call: Sun Pharmaceutical Industries Limited expects FY ‘ 25 R&D spend to be in the range of 7% to 8% of sales

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company expects FY ‘ 25 R&D spend to be in the range of 7% to 8% of sales. Material cost was 20.3% of sales in Q2 FY ‘ 25, lower than the same period last year on account of better product mix. Sun Pharma was ranked #1 and held 8.1% market share in the over Rs. 2,170 billion Indian pharmaceutical market as per AIOCD AWACS MAT Sept-2024; the corresponding market share for the previous period was 7.7%. The company launched 2 generic products in the U.S. in Q2. The company had net cash of $2.6 billion at the consolidated level as of 30th September 2024.

The numbers management gave

Results

  • Material cost was 20.3% of sales in Q2 FY ‘ 25, lower than the same period last year on account of better product mix.
    Show source
    Material cost stands at 20.3% of sales, lower than the same period last year on account of the better product mix.
  • Staff cost was 18.7% of sales in Q2 FY ‘ 25.
    Show source
    Staff cost stands at 18.7% of sales.
  • Other expenses were 32.5% of sales in Q2 FY ‘ 25, higher year-on-year and quarter-on-quarter on account of higher selling and distribution expenses.
    Show source
    Other expenses were 32.5% of sales, higher year-on- year and Q- on- Q on account of higher selling and distribution expenses.
  • The company recorded a FOREX gain of Rs. 1,281 million in Q2 FY ‘ 25, compared to a loss of Rs. 341 million in the same period last year.
    Show source
    FOREX gain for the quarter was Rs. 1,281 million, compared to a loss of Rs. 341 million same period last year.
  • EBITDA, including other operating revenues, was Rs. 39,390 million in Q2 FY ‘ 25, an increase of 23.9% over Q2 last year; EBITDA margin was 29.6%, against 26.1% in Q2 FY ‘ 24 and 28.5% in Q1 FY ‘25.
    Show source
    EBITDA, including other operating revenues, was Rs. 39,390 million for Q2, an increase of 23.9% over Q2 last year, with EBITDA margins for the quarter at 29.6% against 26.1% for Q2 FY ‘ 24 and 28.5% for Q1 FY ‘25.
  • Net profit after tax was Rs. 30,402 million in Q2 FY ‘ 25, up 28% over reported net profit in Q2 last year.
    Show source
    Net profit after tax for Q2 FY ‘ 25 was Rs. 30,402 million, up 28% over the reported net profit of Q2 last year.
Show 19 more statements

Results

  • EPS was Rs. 12.7 per share in Q2 FY ‘ 25.
    Show source
    EPS for the quarter was Rs. 12.7 per share.
  • Material cost was 20.8% of sales in H1, lower than H1 last year, mainly due to product mix, including higher specialty sales.
    Show source
    Material cost for H1 was at 20.8% of sales, lower than H1 last year, mainly due to product mix, including higher specialty sales.
  • Staff cost was 19.1% of sales in H1.
    Show source
    Staff cost stands at 19.1% of sales.
  • Other expenses were 31.7% of sales in H1, higher than H1 last year on account of higher selling and distribution expenses.
    Show source
    Other expenses were at 31.7% of sales, higher than H1 last year on account of higher selling and distribution expenses.
  • The company recorded a FOREX gain of Rs.776 million in H1 compared to a loss of Rs. 321 million for the same period last year.
    Show source
    FOREX gain for H1 was Rs.776 million compared to a loss of Rs. 321 million for the same period last year.
  • EBITDA was Rs. 75,466 million for the first half, a growth of 15.9% over the first half last year, with an EBITDA margin of 29.1%.
    Show source
    EBITDA for the first half was at Rs. 75,466 million, a growth of 15.9% over the first half last year, with resulting EBITDA margin of 29.1%.
  • Net profit was Rs. 58,758 million in H1, up 24.5% over adjusted net profit of H1 last year, excluding the exceptional items of H1 FY ‘ 24.
    Show source
    Net profit for H1 was at Rs. 58,758 million, up 24.5% over adjusted net profit of H1 last year, excluding the exceptional items of H1 FY ‘ 24.
  • India formulation sales were Rs. 42,652 million in Q2 FY ‘25, recording growth of 11% over Q2 last year.
    Show source
    I shall take you through the performance of our India business : For Q2, the sales of formulation in India were at Rs. 42,652 million, recording a growth of 11% over Q2 last year.
  • India formulation sales accounted for 32% of Sun Pharmaceutical Industries Limited’s total consolidated sales in Q2 FY ‘25.
    Show source
    India formulation sales accounted for 32% of total consolidated sales for the quarter.
  • Overall U.S. business sales, including the U.S. portion of Taro, were $517 million in Q2, up about 20.3% over Q2 last year.
    Show source
    For Q2, our overall sales in the U.S. business was up by about 20.3% over Q2 last year, to $517 million.
  • The U.S. accounted for over 33% of Sun Pharmaceutical Industries Limited’s consolidated sales in Q2 FY ‘25.
    Show source
    The U.S. accounted for over 33% of consolidated sales for the quarter.
  • Emerging markets revenue was $293 million in Q2, up 3.2% over Q2 last year; underlying growth in constant currency terms was 5% year-on-year for Q2.
    Show source
    Our revenue in the emerging markets was at $293 million, up by 3.2% over Q2 last year.
  • Emerging markets accounted for 18% of Sun Pharmaceutical Industries Limited’s total consolidated revenue in Q2 FY ‘25.
    Show source
    Emerging markets accounted for 18% of total consolidated revenue for Q2.
  • Formulation revenues in Rest of the World were $199 million in Q2, lower by 3.5% over Q2 FY ‘ 24.
    Show source
    Formulation revenues in Rest of the World were $199 million, lower by 3.5% over Q2 FY ‘ 24.
  • Rest of the World markets accounted for approximately 12.5% of Sun Pharmaceutical Industries Limited’s consolidated Q2 revenues.
    Show source
    ROW markets accounted for approximately 12.5% of consolidated Q2 revenues.
  • Consolidated investments towards R&D were Rs. 7,929 million in Q2 FY ‘ 25, overall 6% of sales; specialty R&D accounted for 38% of total R&D spend for the quarter.
    Show source
    Consolidated investments towards R&D for Q2 FY ‘ 25 stand at Rs. 7,929 million, overall, 6% of sales.
  • Global Specialty sales were up 19.2% to reach $286 million in Q2 FY ’ 25.
    Show source
    Moving to updates on Global Specialty in Q2 FY ’ 25: Our Global Specialty sales were up by 19.2% to reach $286 million.
  • The company said its past field-force expansion was helping it grow faster than the market.
    Show source
    But whatever expansion we have done in the past, I am thinking that it is helping us to grow faster than the market, yes.

Money and capital

  • The company had net cash of $2.6 billion at the consolidated level as of 30th September 2024.
    Show source
    As of 30th September 2024, net cash was $2.6 billion at the consolidated level.

What it expects ahead

What management expects

  • The company expects FY ‘ 25 R&D spend to be in the range of 7% to 8% of sales.
    Show source
    We expect our FY ‘ 25 R&D spend to be in the range of 7% to 8% of our sales.
  • Japan price cuts were an important reason for Sun Pharmaceutical Industries Limited’s Rest of the World revenue decline, and the company expects this pressure to flow through the next few quarters’ performance.
    Show source
    Japan price cuts, as mentioned in the previous quarter, are an important reason for revenue decline in ROW.
  • R&D spend was trending below its full-year guidance due to delays in the start of some clinical studies.
    Show source
    Due to delay in the start of some of our clinical studies, our R&D spend is trending below our guidance for the full year.
  • Utreglutide program will move to the first half of next year. Replaced by a later filing.
    Show source
    Dilip Shanghvi: No, I think if you see our disclosure, what we’ve said is that it will move to the first half of next year.

What it is building and selling

Demand and pricing

  • Sun Pharma was ranked #1 and held 8.1% market share in the over Rs. 2,170 billion Indian pharmaceutical market as per AIOCD AWACS MAT Sept-2024; the corresponding market share for the previous period was 7.7%.
    Show source
    Sun Pharma is ranked #1 and holds 8.1% market share in the over Rs. 2,170 billion Indian pharmaceutical market as per AIOCD AWACS MAT Sept-2024.

Segments

  • The company launched 2 generic products in the U.S. in Q2.
    Show source
    For Q 2, we launched 2 generic products in the U.S. I will now hand over the call to Mr. Shanghvi.
  • Fibromun is an anticancer immunotherapy being investigated in registration trials for the treatment of soft tissue sarcoma and subsequently for glioblastoma.
    Show source
    Fibromun is an innovative anticancer immunotherapy, which is being investigated in registration trials for the treatments of soft tissue sarcoma and subsequently for glioblastoma.

Deals and partners

  • The company entered into a global licensing agreement for commercializing Fibromun, a specialty product from Philogen; Sun Pharma and Philogen S.p.A entered into a global licensing agreement to commercialize Philogen’s specialty product Fibromun (L19TNF).
    Show source
    Sun recently entered into a global licensing agreement for commercializing Fibromun, a specialty product from Philogen.

Everything else said on the call

Other

  • AIOCD AWACS rebased its data from September ‘ 24, leading to lower market share reflections; prior period data was also rebased.
    Show source
    A small note on the new AWACS market share series: From September ‘ 24, AIOCD AWACS has rebased its data leading to lower market share reflections.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Damayanti Kerai: My first question is on R&D spend. So, you mentioned delay in some clinical trials has led to lower R&D spend in first half. And then you mentioned the 7% to 8% range for the full year. So, do you think there will be a significant uptick in the second half R&D spend? And are you seeing pickup in clinical trials, which are currently underway?

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes, I think the new guidance is based on our reassessment of the money that we will need to spend during the second half of the year. And we understand that for the first half, the spend is 6%. For us to reach 7% or 8%, it needs to go up by a corresponding number so that the annual number is reaching the guidance.

  2. Question

    Damayanti Kerai: My second question is on the litigation which you mentioned in your press release for Leqselvi. So, any time line to look at the next update on the IP litigation front? And then you can also please provide some update on your expectation for the launch time line for that product. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY25 Earnings Call Transcript 06:30 pm October 28, 2024 Abhay Gandhi: So, w

    Answer, abhay gandhi

    And I really can’t put time to it, so we do not know, hopefully soon. And as far as readiness for launch is concerned, post the judgment and depending on what the judgment is, we would be ready to launch the product in the market.

  3. Question

    Damayanti Kerai: But have you done sufficient preparation to launch immediately once the court ruling comes favorably? Or will it take some time?

    Answer, abhay gandhi

    Abhay Gandhi: It will be a couple of weeks, not definitely a couple of months. So, to that extent, we will be ready.

  4. Question

    Anubhav Agarwal: Just first question is on Leqselvi litigation itself. I am just trying to understand the scope of this litigation. So, based on my reading, the litigation is mainly on 335 patent, where the expiry of this patent is December ‘26, which is like 2 years from now. So, two subparts to this question. One is, is the scope of litigation only for 2 years or the scope of litigation is beyond the 2 years as well? That’s one part of my question. And the second part of the question is that in terms of worst -case outcome, what is the worst outcome here that does Sun have to pay a higher royalty here? Or you may not be able to launch the drug itself for 2 years?

    Answer, dilip shanghvi

    Dilip Shanghvi: So, as we understand the litigation, I think is the scope of the litigation is correct. I think the patent which they are using to litigate has an expiry date. And up to that is the worst-case situation is that in case if we get an unfavorable judgment and then even on appeal if we lose, then that is the time to which our potential launch gets delayed.

  5. Question

    Anubhav Agarwal: And Dilip bhai, on the second part of the question, so is this more the worst case on the extent of royalty that we need to pay with 10 %, 20%? Or is it like do not launch at all for 2 years?

    Answer, dilip shanghvi

    Dilip Shanghvi: No. I think generally, royalty in such a situation would be subject to a settlement. It cannot be arbitrarily defined as to what would be t he royalty and whether with a royalty, we can launch or not. It ’s a binary outcome.

  6. Question

    Anubhav Agarwal: And the second question was on the ILUMYA. Today, when you are in the Medicare Part B market, the medical benefit product, what percentage of prescriptions are you missing already because you do not have approval of psoriatic arthritis. So, I am just trying to understand, let’s say, a year down the line, if the Phase - Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY25 Earnings Call Transcript 06:30

    Answer, abhay gandhi

    Abhay Gandhi: So, typically, I mean, if I look at the other competitors in the market and their data, and also from conversations with doctors, the split between psoriasis and psoriatic arthritis is somewhere, and you can use this as a ballpark figure, so don’t hold me to it, it’ s like a 70-30. So, the 30% is the market you are roughly kept around with. And this is data that you can also validate in the public domain of the others.

  7. Question

    Anubhav Agarwal: Abhay, that’s correct. But my question was that, if ILUMYA already being prescribed on off-label basis for those patients as well, so is the incremental gain not 30%? Or is it lower? Or your sense is that benchmark or a heurist ic benchmark of 30% is still valid for Sun as well?

    Answer, abhay gandhi

    Abhay Gandhi: I mean, Anubhav, how do you expect me to comment on any off -label use.

    Answer, dilip shanghvi

    Dilip Shanghvi: I think if you say, we have no prescription from rheumatologists. And if a dermatologist is prescribing for psoriatic arthritis, we wouldn’ t know. But most likely in the U.S. context, they wouldn’ t prescribe.

    Answer, abhay gandhi

    Abhay Gandhi: And Anubhav, you need to also appreciate that if there are other products available whose label mentions the psoriatic arthritis, then the motivation of the doctor to use another product off-label is also very low.

  8. Question

    Neha Manpuria: My first question is on Winlevi. Abhay sir, given the change that we had in strategy, you talked about it a few quarters back. If I look at the IQVIA data, obviously, the trend seems to be not reflecting that change. Are we seeing an improvement in Winlevi sales quarter-on- quarter? Is it in line with our expectation? And what should we expect in terms of when should we start seeing that prescription traction picking up given that we’ve changed the strategy only a couple of quarters back?

    Answer, abhay gandhi

    Abhay Gandhi: So, we did expect the fall in prescription post our changes in strategy, which is what I think Dilip sir explained on the previous call as well. The focus was on generating a more profitable prescription. I think Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY25 Earnings Call Transcript 06:30 pm October 28, 2024 we’ve been able to achieve that. That’s why the numbers are good. Now on that lower base of prescription that we have, I think our task becomes to grow on that quarter-on- quarter.

  9. Question

    Neha Manpuria: And when do you think we get to, let’s say, a sustainable level of prescription that you would be happy about? Would it take us a couple of quarters, a couple of years? When do you think we get there?

    Answer, abhay gandhi

    Abhay Gandhi: Honestly, I am already happy with the traction that we are seeing. And if I am able to grow the revenues with a more profitable prescription, then I am already happy. But having said that, I mean, the idea is to continue to grow prescriptions in whichever product we market, not only in the U.S. but in any other geography. I don’ t have a set goal in mind that at this point, I’ll be happy.

  10. Question

    Neha Manpuria: And sir, the focus in these markets would be growth over profitability. I mean, because each of them are separate markets, how should we think about the growth versus profitability in these markets because there’s a fairly large mix of markets?

    Answer, dilip shanghvi

    Dilip Shanghvi: The way our budgeting process works is that every country is expected to grow both top line as well as bottom line, irrespective of the size of the market. The focus from the business point of view would be that the corporate office, the business development team as well as the priority for R&D resources would be allocated to these geographies before they are available to the other geographies. So, that’s the essential difference.

Show 25 more questions
  1. Question

    Bino Pathiparampil: On the specialty side, this Fibromun which we have in- licensed recently, I believe it’s in registration trials. Any time line regarding completion of those trials?

    Answer, dilip shanghvi

    Dilip Shanghvi: No. I think we’ve also indicated that the trial is managed by the principle from whom we have licensed the product, and they are a public company. So, until they, what you call, disclose what is their time line for filing. However, we have seen before we licensed the clinical outcome data and we feel that it’ s an exciting opportunity for patients who are currently significantly undertreated for this disease.

  2. Question

    Bino Pathiparampil: And sir, for Utreglutide, you were planning to start the Phase -II in the second half of this year. Is that on track? Have you started it?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think if you see our disclosure, what we’ve said is that it will move to the first half of next year.

  3. Question

    Surya Patra: Sir, first question is on the R&D spend. While we have become a bit aggressive about adding more and more specialty pipelines, we had indicated about 8% to 10% kind of R&D spend, and now we are cutting down to 7%, 8% kind of for the current year. So, how should one think whether it is because of the savings that is coming from the in-house capability, clinical capability, what you have indicated that you are building it up. So, it’s a benefit of that? Or it is just deferral of certain things that we have seen in the first half, that as a result of that is the number is reducing?

    Answer, dilip shanghvi

    Dilip Shanghvi: So, what your question is whether it’s an intentional delay or whether it’s the reason why -- because of any other reason, the -- Surya Patra: Yes.

  4. Question

    I mean, whether it is the saving that is coming from the in-house clinical capabilities, what you’ re building it up. So, that has brought in this kind of saving, or it is something else? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY25 Earnings Call Transcript 06:30 pm October 28, 2024 Dilip Shanghvi: No. I think there is also a delay in commissioning some of the studies.

    Answer, dilip shanghvi

    So, it’s not only in- house saving from managing the studies. It’s still a long time before we get to know whether there is any significant saving because of the change in the, what you call, organizational capability.

  5. Question

    Surya Patra: No. I mean, since U.S. is the majority of the Global Specialty. So, if I reframe that, U.S. sales growth is higher than the Global Specialty growth. The reverse trend used to be the kind of a trend. So, what is driving this U.S. business? Because the base business of plain-vanilla generic is obviously facing its own challenges. So, what is driving? Whether it is something coming from the Taro side? Or what is driving the forces, if you can just indicate and your outlook for the base business also?

    Answer, abhay gandhi

    Abhay Gandhi: I think the reason is pretty obvious. Our major products, whether it is ILUMYA, Winlevi, ODOMZO or CEQUA,have done well. And the team continues to perform and deliver. That ’s the reason.

    Answer, dilip shanghvi

    Dilip Shanghvi: See, my understanding, they’re trying to reconstruct specialty and generic separately. In the past, they were doing because Taro numbers were public. So, they were able to reconstruct. So, no, I think we need to internally debate and understand whether we want to share more information than what we are already sharing.

  6. Question

    Surya Patra: Just one last update, sir. This Chinese Ilumetri launch, whether we have seen any meaningful progress there? Any influence that we can see to our ROW sales?

    Answer, dilip shanghvi

    Dilip Shanghvi: I think we are very happy with the kind of traction Ilumetri has received in a relatively short period of time after launching the product in China. And we expect it to become a more meaningful product as time progresses.

  7. Question

    Shashank Krishnakumar: My first question was on the domestic piece. So, when we are alluding to volume- led growth, would there be a meaningful difference in terms of volume growth across town classes that you ’re seeing in our portfolio? Would volume growth be meaningfully higher in metros and Tier 1 towns for us as opposed to, say, class 2 to 4 towns and rural markets? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2

    Answer, kirti ganorkar

    But what I can tell you, our volume growth is quite strong, and the volume growth for the industry is on MAT September ‘24 basis is 0.7% and we are 5.2%. So, strong, and I see that is across the businesses. Maybe geography wise, I don’ t have the data to share with you, but it is across the businesses.

  8. Question

    Shashank Krishnakumar: My second question was on SCD-044. So, I understand that Amgen has received an approval for Otezla for pediatric use. And while this is an age group where there is no other approved option right now. So, is that a patient population group that we could also potentially target?

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes. I think we are waiting for the Phase- II data to come and then we ’ll decide because many times, the agency also requires that on approval that you have to do a pediatric study to get the product approved for pediatric patients and psoriasis as well as atopic dermatitis are both conditions for which there is a sizable number of pediatric patients. So, in this case, there is a business case, but we have to take a decision looking at the Phase- II data. But in any case, most of the people that develop the product first for the adult population and then go back to the pediatric.

  9. Question

    Anubhav Agarwal: So, what explains this is almost Rs. 450 crores increase in quarter?

    Answer, dilip shanghvi

    Dilip Shanghvi: So, there would also be a ramp- up cost for launching Leqselvi, which are coming to the expenses for the first time.

  10. Question

    Anubhav Agarwal: But would you say, Dilip bhai, that this is the new base of other expense for us?

    Answer, dilip shanghvi

    Dilip Shanghvi: I mean, generally, we don’t guide for expenses, but I think our focus would be to run the business most efficiently. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY25 Earnings Call Transcript 06:30 pm October 28, 2024 Anubhav Agarwal: Second question is on Leqselvi, actually not just on Leqselvi drug, but on the alopecia areata market.

  11. Question

    So, just trying to understand that there are 2 existing drugs in the market and the ramp- up has been slow in last 2 years of the market formation. So, out of the 2 factors, which I can think of, just trying to understand which is the bigger factor, which is leading to a slower ramp up of the market? One is insurance access or insurance coverage as factor one. And second is doctor’s lack of willingness to prescribe this category because of the black box warning on the JAK inhibitor class. So, out of these 2 factors or maybe third or fourth factor, which you guys can help think about that. Because when I see the 2 drugs on IQVIA, I only see less than 15,000 patients being treated in total on

    Answer, abhay gandhi

    Abhay Gandhi: See, in the U.S., access always builds up gradually. It is not that the day you launch, you will get unrestricted full access across all the payer groups. Some of them have a new-to-market block. So, I think you should also look at access as a continuum rather than event upon launch.

  12. Question

    Anubhav Agarwal: But Abhay, is access the only reason why the -- Abhay Gandhi: See, one of the products also has multiple indications.

    Answer, abhay gandhi

    It also depends on where a company may or may not focus. I cannot speak for anybody else. But our focus will be on growing both awareness as well as usage of our product in that indication. So, waiting to get to market and then we will see whether we can grow the market as well.

  13. Question

    Vivek Agrawal: So, my question is related to your obesity molecule, GL0034, right? You presented Phase -I data in June 2023. And now you post the Phase -II trials in 2025, right? So, it’s more than 2 years and the gap seems to be substantial, right? So, just trying to understand why there is a big gap of 2 years, either you lack confidence in Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY25 Earnings Call Transcrip

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think we are very excited. I don’t know whether you kept track. But otherwise, we’ve been consistently presenting the clinical outcome data, both in healthy subjects as well as in patients. And I think, we believe that we have a very, what I would call, best-in-class product. There is a certain amount of delay in terms of starting the large Phase -II study. But we hope that we will be able to make up during the conduct of the study.

  14. Question

    Vivek Agrawal: And sir, is it also fair to understand that your R&D spend are expected to move up substantially once you start the Phase -II trial of this particular molecule? Or irrespective of this particular molecule, should we expect R&D spend to go up substantially and to go up in the 8%, 9% kind of range?

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes, we will cover it in our guidance.

  15. Question

    Saion Mukherjee: Sir, my first question is the intangible assets under development that we see has risen quite a lot in 6 months. So, can you explain what is driving this?

    Answer, c muralidharan

    C. Muralidharan: So, this increase in the intangible asset development, as I just said now, is for the Fibromun product which we have contracted licensed from Philogen. Saion Mukherjee: And my second question is on the psoriatic arthritis indication for ILUMYA. Would this require approaching rheumatologists separately? I mean, do you need to make any additional investments for that indication?

    Answer, abhay gandhi

    Abhay Gandhi: So, we will definitely have to cover the rheumatologists. We are still trying to figure out how. So, I don’ t have a complete fix on what will we need to do. We still have time. But it’ s work-in-progress. But yes, we will have to cover the rheum segment definitely.

  16. Question

    Saion Mukherjee: But is it possible, sir, to sort of license out or work with some existing player in that segment?

    Answer, abhay gandhi

    Abhay Gandhi: I don ’t think it will be necessary. I think on our own, we’ll be able to do a good job.

    Answer, abhay gandhi

    Abhay Gandhi: I think in more ways than one, I have answered the question. But the last way I can attempt is year-on- year, the generic business without Revlimid has shown growth. But quarter-on- quarter, it’s a small decline.

  17. Question

    Rahul Jeewani: And the second question which I had was on the domestic business. So, can you talk about your rep expansion plans for the domestic market given that, let’s say, a year back, we had added almost 1000 new reps to the domestic business. So, what are your rep expansion plans going forward?

    Answer, kirti ganorkar

    Kirti Ganorkar: I think I shared in the past is like we have expanded our field force. And today, we have 14,000 people on the ground who are promoting product to the doctors. So, about future plans, we can’t comment it. But whatever expansion we have done in the past, I am thinking that it is helping us to grow faster than the market, yes.

  18. Question

    Rahul Jeewani: Sure, sir. So, sir, just a follow-up on that. So, do you think that the existing field force, which we have, that can continue this volume-led outperformance for us in the domestic market? Or let’s say, when do you anticipate the next round of expansion happening on the rep side, even if you are not willing to call out the exact number as such?

    Answer, kirti ganorkar

    Kirti Ganorkar: No, that’s what I said. We can’t disclose our strategic plan when we want to expand in the business. These are the calls we take during our budgets every year .

  19. Question

    Madhav Marda: Yes. Just two questions. The first one was on the PSA indication. In case we get the favorable Phase- III data in H2 CY ‘25, what could be the earliest launch for the PSA indication for ILUMYA? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY25 Earnings Call Transcript 06:30 pm October 28, 2024 Abhay Gandhi: So, the attempt always is that whether it’s a launch of a new product or a new indication, you

    Answer, abhay gandhi

    So, we will always attempt to do it as soon as we get the approval.

  20. Question

    Madhav Marda: In case the Phase -III is favorable?

    Answer, abhay gandhi

    Abhay Gandhi: We will launch as soon as we get approval in the new indication. And like I said, for another product which was asked, it will be a matter of a few weeks and not a few months.

  21. Question

    Naresh Suthar: Right, correct.

    Answer, dilip shanghvi

    Dilip Shanghvi: I don’ t think your assessment and our understanding is correct. Our understanding is that the new product that Taro used to file, and launch justified the money that was spent. But there was a steep price cut across other products, which was made up by this, but the overall rate of decline was significantly faster compared to the other products that we had in our portfolio.

  22. Question

    Neha Manpuria: My first question is on M&A. Given that that’s been a core part of our strategy in building out the specialty pipeline so far, I just wanted to get your sense on the environment today for specialty assets in the U.S. We’ve heard about the biotech funding crunch, big pharma sort of looking at assets given they sort of constrain the R&D. Is it more difficult to get specialty assets for acquisition? And is that the reason for us becoming more aggressive in terms of building our own clinical capabilities? I just wanted to understand the long- term pipeline strategy for the specialty business.

    Answer, dilip shanghvi

    Dilip Shanghvi: So, I think the buildup of the clinical capability is more a function of at which stage we are able to or actually decide to license a product. If we decide to license a product which is, let’s say, completed Phase - III, then we don’t need a big asset, I mean, organization. We license a product in Phase- II or earlier, then we will need an organization which can bring the product to market from Phase- II. And our sense is that it’s better for us to also look at a mix of products which are close to market or also products that we can develop on our own.

  23. Question

    Neha Manpuria: And sir, is it becoming more difficult for us to get, let’s say, near commercial products for acquisition in the existing focus areas that we have, in ophtha and derma and oncology.Is that the sense that you get when you look at the market, M&A market?

    Answer, dilip shanghvi

    Dilip Shanghvi: I mean, actually, I have no historical context. So, I can’t compare that 10 years back it was easier and now it is difficult. But I don’ t see a situation where if we are interested in an asset. And since our area of focus is relatively narrow, not many competing potential bidders.

  24. Question

    Neha Manpuria: And my second question is on ILUMYA. Because ILUMYA prescription traction continues to be very good. Obviously, we had skepticism about biosimilars impacting that. We have another biosimilar launch Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com , Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY25 Earnings Call Transcript 06:30 pm October 28, 2024 coming next year. What’s essentially driving the growth in ILUMYA prescription? And do you think despite

    Answer, abhay gandhi

    Abhay Gandhi: I mean, many factors go into it. But at the end of the day, it’s about execution on the strategy. And it’s a multifactorial product sell. It’s not an easy sell. And I think we are able to execute on multiple fronts to keep that engine moving.

  25. Question

    Neha Manpuria: And you don’t think another biosimilar in one of the other large products sort of impacts ILUMYA prescription growth?

    Answer, abhay gandhi

    Abhay Gandhi: So, to be perfectly honest, I mean, we are, in the overall market, a relatively small player as compared to the big ones. So, I think any biosimilar will go after the big fish, and not necessarily the space that we are playing. So, I guess to that extent, I mean, we are relatively insulated as compared to the bigger products.

Questions about this call

When was the Sun Pharmaceutical Industries Q2 FY25 earnings call transcript filed?
Sun Pharmaceutical Industries filed the transcript with the exchange on 4 Nov 2024. This page is built from that transcript.
What does this page list?
34 statements from the transcript across 7 topics, 28 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 35 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Sun Pharmaceutical Industries Q2 FY25 concall: Sun Pharmaceutical Industries Limited expects FY ‘ 25 R&D spend to be in the range of 7% to 8% of sales · DalalOS